Island Pharmaceuticals Limited

Island Pharmaceuticals Limited

ILA.AX
Island Pharmaceuticals LimitedAU flagAustralian Securities Exchange
0.37
AUD
+0.01
- -
92.52MMarket Cap
Island Pharmaceuticals Limited
ILA.AX
(Australian Securities Exchange)

Recent

price

0.37

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
FRC
- -
- -
- -
0.01
- -
Revenue per Share
-0.11
-0.03
-0.03
-0.03
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
0.88
0.17
- -
0.01
- -
Book Value per Share
0.32
0.05
0.02
0.02
- -
Tangible Book Value per Share
20
87
88
90
173
Basic Weighted Avg Shares
- -
- -
- -
1
- -
Sales/Revenue/Turnover
- -
- -
-26,182.25
-229.61
- -
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
-2
-3
-3
-3
- -
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-25,580.2
-228.86
- -
Profit Margin (%)
6
4
2
2
- -
Working Capital
- -
- -
- -
- -
- -
LT Debt
6
4
2
2
- -
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-15.86
-36.99
-430.31
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.03
2024
- -
- -
- -
- -
-0.03
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Business
Island Pharmaceuticals Limited (ASX:ILA) is a clinical-stage pharmaceutical company focused on developing and commercializing innovative treatments for infectious diseases and reproductive health. The company offers a pipeline of product candidates including IXP1603, a long-acting tenofovir alafenamide formulation for HIV pre-exposure prophylaxis; BUL-001, a reformulated misoprostol for reproductive health indications such as labour induction and postpartum hemorrhage prevention; and other antiviral and antimicrobial therapies targeting unmet needs in global health. Island's products emphasize reformulation technologies to improve patient compliance, efficacy, and accessibility, particularly in low- and middle-income countries. Founded in 2019 and headquartered in Sydney, Australia, the company operates primarily in Australia with clinical trials and partnerships extending to the United States, Europe, and Asia-Pacific regions. In late 2024, Island announced a strategic collaboration with a leading global health organization to advance BUL-001 into Phase III trials, alongside securing a A$10 million funding round to support pipeline expansion and manufacturing scale-up.

Company News

APIChat
  • Island Pharmaceuticals inks US Army research deal to advance Marburg antiviral program